On May 17, Hims & Hers Health raised its 2026 revenue guidance to $3 billion, exceeding market expectations. The company maintains a long-term target of at least 20% EBITDA margins by 2030. However, it faces short-term margin pressures from branded GLP-1 drugs and international scaling.
The biotech firm delivered strong Q1 revenue growth to $230M, driven by commercial momentum in radiopharmaceuticals and a strategic collaboration with Regeneron.
Read the full storyUber surpassed Q1 profit expectations and forecast robust Q2 gross bookings, supported by resilient demand for its Mobility and Delivery segments.
The FDA placed a clinical hold on ARD-101 due to unexpected cardiac signals, leaving the stock trading near its cash value.
Fitch Ratings upgraded Teva to BBB- from BB+ with a stable outlook, citing improved financial stability and the execution of its growth strategy.
Alphabet reported 21.8% revenue growth and a $462B cloud backlog, signaling strong demand for AI-integrated services despite rising infrastructure costs.
The company reaffirmed its 2024 revenue guidance following the Stericycle acquisition, with analysts projecting a 21% upside potential for the stock.
CAVA stock has fallen over 20% from its yearly high, entering a technical bear market as investors pivot focus to the upcoming quarterly results.
The telehealth provider raised its long-term revenue outlook above consensus, targeting 20% EBITDA margins by 2030 despite near-term pressures from international scaling.